Clinical Trials Browser

Phase 2 × Metastatic Gastric Adenocarcinoma × S 1 (combination) × Clear all

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Metastatic Gastric Adenocarcinoma